[Hot Stock] HL Biopharma Surges on Subsidiary's Dendritic Cell Vaccine Clinical Results
[Asia Economy Reporter Geum Bo-ryeong] HL Biotech surged following news of clinical trial results for the dendritic cell vaccine 'ITI-1000' targeting glioblastoma by its subsidiary Immunomic Therapeutics.
As of 1:37 PM on the 2nd, HL Biotech's stock price rose 12.07% (10,900 KRW) from the previous close to 101,200 KRW.
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- Trump Pressures Taiwan to Relocate Semiconductor Industry to U.S., Says "Taiwan Took Away America's Semiconductor Industry"
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
HL Biotech's subsidiary Immunomic Therapeutics announced the clinical trial results of the dendritic cell vaccine ITI-1000 through 'Clinical Cancer Research,' published by the American Association for Cancer Research. The study showed that the 5-year survival rate of patients treated with ITI-1000 was approximately 35%, about seven times higher than the 5% survival rate with existing treatments.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
